Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study.

PubWeight™: 1.34‹?› | Rank: Top 10%

🔗 View Article (PMID 21530398)

Published in Lancet Oncol on May 01, 2011

Authors

Mariëlle Kocken1, Theo J M Helmerhorst, Johannes Berkhof, Jacqueline A Louwers, Mariëlle A E Nobbenhuis, Aagje G Bais, Cornelis J A Hogewoning, Afra Zaal, René H M Verheijen, Peter J F Snijders, Chris J L M Meijer

Author Affiliations

1: Department of Obstetrics and Gynaecology, Erasmus MC University Medical Center, Rotterdam, Netherlands.

Associated clinical trials:

Intraoperative HPV Testing Evaluation | NCT04190472

Articles citing this

Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study. BMJ (2012) 2.05

Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality. BMJ (2014) 1.61

Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management. J Low Genit Tract Dis (2013) 0.90

The Clinical Role of HPV Testing in Primary and Secondary Cervical Cancer Screening. Obstet Gynecol Int (2013) 0.88

The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review. Gynecol Oncol (2014) 0.80

Posttreatment human papillomavirus testing for residual or recurrent high-grade cervical intraepithelial neoplasia: a pooled analysis. J Gynecol Oncol (2015) 0.80

Residual disease and HPV persistence after cryotherapy for cervical intraepithelial neoplasia grade 2/3 in HIV-positive women in Kenya. PLoS One (2014) 0.79

Human papillomavirus type-specific persistence and reappearance after successful conization in patients with cervical intraepithelial neoplasia. Int J Clin Oncol (2015) 0.78

Recurrence of cervical intraepithelial lesions after thermo-coagulation in HIV-positive and HIV-negative Nigerian women. BMC Womens Health (2016) 0.78

Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma. Ecancermedicalscience (2015) 0.78

Positive Surgical Margin, HPV Persistence, and Expression of Both TPX2 and PD-L1 Are Associated with Persistence/Recurrence of Cervical Intraepithelial Neoplasia after Cervical Conization. PLoS One (2015) 0.76

Cervical cancer: squamocolumnar junction ablation--tying up loose ends? Nat Rev Clin Oncol (2015) 0.76

Past and future of prophylactic ablation of the cervical squamocolumnar junction. Ecancermedicalscience (2015) 0.76

Deciphering the Multifactorial Susceptibility of Mucosal Junction Cells to HPV Infection and Related Carcinogenesis. Viruses (2017) 0.75

HPV-Testing in Follow-up of Patients Treated for CIN2+ Lesions. J Cancer (2016) 0.75

Pregnancy outcomes after treatment for preinvasive cervical lesions. BMJ (2016) 0.75

Long-Term Clinical Outcome after Treatment for High-Grade Cervical Lesions: A Retrospective Monoinstitutional Cohort Study. Biomed Res Int (2015) 0.75

E6/E7 mRNA testing for human papilloma virus-induced high-grade cervical intraepithelial disease (CIN2/CIN3): a promising perspective. Ecancermedicalscience (2015) 0.75

Articles by these authors

Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67

WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14

Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med (2002) 10.80

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med (2010) 8.10

Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer (2004) 6.99

Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst (2003) 6.28

Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer (2006) 5.87

GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol (2002) 5.63

Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer (2011) 5.43

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28

Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet (2002) 5.00

Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine (2008) 4.82

Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med (2008) 4.33

A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer (2007) 4.29

Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst (2006) 4.14

Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet (2002) 3.96

Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst (2004) 3.67

Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64

Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol (2011) 3.58

Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer (2006) 3.38

Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine (2006) 3.15

Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol (2006) 3.13

Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ (2002) 3.09

Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine (2012) 3.09

POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer (2004) 2.89

Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood (2007) 2.82

Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst (2002) 2.75

Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol (2011) 2.52

Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol (2005) 2.42

Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. Clin Infect Dis (2005) 2.20

Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol (2006) 2.20

Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis. Am J Surg Pathol (2013) 2.19

Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol (2005) 2.15

HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ (2010) 2.10

The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J Infect Dis (2005) 2.07

The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol (2003) 2.04

HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol (2006) 2.03

Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol (2008) 2.00

Smoking and cervical cancer: pooled analysis of the IARC multi-centric case--control study. Cancer Causes Control (2003) 2.00

Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer (2002) 1.98

Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol (2003) 1.96

Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis (2003) 1.93

Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia (2004) 1.92

The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res (2009) 1.87

Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev (2010) 1.85

Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC). Arch Dermatol (2008) 1.78

Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol Biomarkers Prev (2006) 1.77

Human papillomavirus and risk factors for cervical cancer in Chennai, India: a case-control study. Int J Cancer (2003) 1.77

Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer (2003) 1.74

Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes--implications for cost-effectiveness analyses. Int J Epidemiol (2004) 1.73

High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer (2012) 1.71

Human papillomavirus infection among women in South and North Vietnam. Int J Cancer (2003) 1.71

Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev (2005) 1.71

Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer (2003) 1.71

Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer (2010) 1.69

Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood (2008) 1.69

EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol (2004) 1.68

Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine (2012) 1.68

Effects of daily events on mood states in major depressive disorder. J Abnorm Psychol (2003) 1.67

Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer (2004) 1.62

Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types. J Clin Microbiol (2006) 1.61

The natural course of asymptomatic Chlamydia trachomatis infections: 45% clearance and no development of clinical PID after one-year follow-up. Int J STD AIDS (2002) 1.60

HPV16 and increased risk of recurrence after treatment for CIN. Gynecol Oncol (2006) 1.59

Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol (2003) 1.58

Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer. J Clin Oncol (2007) 1.58